Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC ACT-1004-1239 | 2178049-58-4 | 98.81% | C27H28F2N6O3 | 25 MG
Supplier: Medchemexpress LLC 25MGHY142617
ACT-1004-1239 is a potent, selective, and orally active CXCR7 antagonist with an IC50 value of 3.2 nM, developed for research purposes only. This compound promotes oligodendrocyte precursor cell differentiation and has shown promise in reducing disease severity in models of inflammatory demyelinating diseases.
- Potent and selective CXCR7 antagonist
- Orally active with an IC50 of 3.2 nM
- Promotes oligodendrocyte precursor cell (OPC) differentiation
- Increases plasma CXCL12 concentration in mice
- Reduces disease severity in MOG-induced experimental autoimmune encephalomyelitis (EAE) model
- Increases myelination in Cuprizone-induced demyelination model mice
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?